Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg. Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose ...

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it. Transcription factors ...

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously “undruggable” cancer protein target, permanently blocking it. Transcription factors ...

At the ongoing meeting of the American Chemical Society in Denver, F. Hoffmann-La Roche Ltd. has reported the discovery of an orally available and brain-penetrant irreversible asparagine-specific ...

Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a co-factor that controls transcription by phosphorylating the C-terminal domain of ...

Medical University of South Carolina researchers develop a new lysine-specific demethylase 1 (LSD1) inhibitor and evaluate its effects in the rare pediatric cancer neuroblastoma. A Medical University ...

Jaypirca was approved for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were previously treated with a covalent Bruton ...

BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLL BMF-219, a covalent menin inhibitor, demonstrated potency across ex vivo ...

Median progression-free survival in patients with advanced non–small-cell lung cancer treated with EGFR tyrosine kinase inhibitors is 11 months. Is there a more efficacious treatment? New research ...